Daratumumab increases progression-free survival in newly diagnosed myeloma patients ineligible for transplantMyelomaDecember 5, 2018
New data presented at ASH 2018 from an ongoing phase I clinical trial of CAR T cell therapy in relapsed/refractory myelomaConferences, MyelomaDecember 4, 2018